• Citations Per Year
Learn More
PURPOSE Preclinical studies demonstrated anti-tumor efficacy of the combination of the histone deacetylase (HDAC) inhibitor romidepsin plus erlotinib in non-small cell lung cancer (NSCLC) models that were insensitive to erlotinib monotherapy. We therefore studied this combination in a phase 1 clinical trial in previously treated advanced NSCLC. METHODS(More)
Epidermal growth factor receptor (EGFR) overexpression plays an important oncogenic role in cancer. Regular EGFR protein levels are increased in cancer cells and the receptor then becomes constitutively active. However, downstream signals generated by constitutively activated EGFR are unknown. Here we report that the overexpressed EGFR oscillates between(More)
AIMS β-Lapachone (β-lap), a novel radiosensitizer with potent antitumor efficacy alone, selectively kills solid cancers that over-express NAD(P)H quinone oxidoreductase 1 (NQO1). Since breast or other solid cancers have heterogeneous NQO1 expression, therapies that reduce the resistance (e.g., NQO1(low)) of tumor cells will have significant clinical(More)
tetracycline exposure (24h, 1μg/ml) were treated with EGF for 15 minutes followed by preparation of lysates and Western blot with the indicated antibodies. (b) U87V or U87EGFR cells were treated with EGF for 15 minutes followed by preparation of lysates and Western blot with the indicated antibodies. (c) Tyrosine phosphorylation of the EGFR at residues 845(More)
  • 1